BIO-RAD LABORATORIES, INC. (BIO)
BIO-RAD LABORATORIES, INC. (BIO)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash received from customers | 614,100 | 697,700 | 653,800 | 1,304,900 |
| Cash paid to suppliers and employees | 515,800 | 547,500 | 517,500 | 993,900 |
| Interest paid, net | 22,400 | 1,100 | 22,400 | 23,100 |
| Income tax payments, net | 11,000 | 7,300 | -1,800 | 56,100 |
| Investment proceeds and miscellaneous receipts, net | 33,300 | 18,300 | 13,800 | 48,900 |
| (payments for) proceeds from forward foreign exchange contracts, net | NaN | -38,100 | NaN | NaN |
| Proceeds from forward foreign exchange contracts, net | -52,800 | NaN | 8,600 | 34,300 |
| Net cash provided by operating activities | 108,100 | 164,900 | 120,900 | 246,400 |
| Capital expenditures | 30,000 | 45,800 | 31,700 | 80,100 |
| Proceeds from dispositions of property, plant and equipment | 100 | 0 | 0 | 100 |
| Proceeds from divestiture of a division | NaN | 0 | NaN | NaN |
| Payments for business acquisitions, net of cash received | NaN | 0 | 1,800 | 216,700 |
| Payments for acquired in-process research and development | NaN | 0 | 0 | NaN |
| Payments for purchases of marketable securities and investments | 226,100 | 138,800 | 223,900 | 306,600 |
| Proceeds from sale of debt securities, available-for-sale | 145,100 | 147,400 | 200,600 | 445,600 |
| Proceeds from maturities of marketable securities and investments | 17,700 | 3,000 | 13,800 | 45,200 |
| Proceeds from issuance of common stock and from reissuance of treasury stock under the employee stock purchase plan and upon exercise of stock options | NaN | 15,800 | NaN | NaN |
| Net cash used in investing activities | -93,200 | -34,200 | -43,000 | -112,500 |
| Tax payments from net share settlement | NaN | 400 | 2,500 | 100 |
| Payments on long-term borrowings | 100 | 200 | 0 | 300 |
| Payments for debt issuance costs | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock | -8,500 | NaN | 3,400 | 8,500 |
| Payments for purchases of treasury stock | 47,800 | 0 | 53,400 | 242,100 |
| Payments of contingent consideration | NaN | 0 | NaN | NaN |
| Option premium proceeds for structured purchases of treasury stock | 500 | NaN | NaN | NaN |
| Net cash used in financing activities | -44,000 | 3,300 | -52,500 | -234,000 |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | NaN | -16,900 | NaN | NaN |
| Effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents | 22,800 | NaN | 1,100 | -18,000 |
| Cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect | -23,200 | 134,000 | 26,500 | -118,100 |
| Beginning cash, cash equivalents, and restricted cash | 532,200 | 91,600 | 489,800 | NaN |
| Ending cash, cash equivalents, and restricted cash | 509,000 | 134,000 | 398,200 | NaN |